440 related articles for article (PubMed ID: 27364962)
41. Alpha-Synuclein in Alcohol Use Disorder, Connections with Parkinson's Disease and Potential Therapeutic Role of 5' Untranslated Region-Directed Small Molecules.
Cahill CM; Aleyadeh R; Gao J; Wang C; Rogers JT
Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33096655
[TBL] [Abstract][Full Text] [Related]
42. Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity.
Ghanem SS; Fayed HS; Zhu Q; Lu JH; Vaikath NN; Ponraj J; Mansour S; El-Agnaf OMA
Molecules; 2021 Jun; 26(12):. PubMed ID: 34205249
[TBL] [Abstract][Full Text] [Related]
43. Patient-specific pluripotent stem cell-based Parkinson's disease models showing endogenous alpha-synuclein aggregation.
Oh Y
BMB Rep; 2019 Jun; 52(6):349-359. PubMed ID: 31186086
[TBL] [Abstract][Full Text] [Related]
44. Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?
Oueslati A
J Parkinsons Dis; 2016; 6(1):39-51. PubMed ID: 27003784
[TBL] [Abstract][Full Text] [Related]
45. α-Synuclein and Parkinsonism: Updates and Future Perspectives.
Rosborough K; Patel N; Kalia LV
Curr Neurol Neurosci Rep; 2017 Apr; 17(4):31. PubMed ID: 28324300
[TBL] [Abstract][Full Text] [Related]
46. Association of SNCA variants with α-synuclein of gastric and colonic mucosa in Parkinson's disease.
Chung SJ; König IR; Lohmann K; Hinrichs F; Kim J; Ryu HS; Lee HJ; Kim K; Lee JH; Jung KW; Kim MJ; Kim MJ; Kim YJ; Yun SC; Hong SM; Myung SJ; Klein C
Parkinsonism Relat Disord; 2019 Apr; 61():151-155. PubMed ID: 30424941
[TBL] [Abstract][Full Text] [Related]
47. Mechanistic Insight into the Binding Profile of DCVJ and α-Synuclein Fibril Revealed by Multiscale Simulations.
Kuang G; Murugan NA; Ågren H
ACS Chem Neurosci; 2019 Jan; 10(1):610-617. PubMed ID: 30277753
[TBL] [Abstract][Full Text] [Related]
48. (-)-epigallocatechin-3-gallate (EGCG) maintains kappa-casein in its pre-fibrillar state without redirecting its aggregation pathway.
Hudson SA; Ecroyd H; Dehle FC; Musgrave IF; Carver JA
J Mol Biol; 2009 Sep; 392(3):689-700. PubMed ID: 19616561
[TBL] [Abstract][Full Text] [Related]
49. Could α-synuclein amyloid-like aggregates trigger a prionic neuronal invasion?
Busquets MA; Espargaró A; Estelrich J; Sabate R
Biomed Res Int; 2015; 2015():172018. PubMed ID: 25866763
[TBL] [Abstract][Full Text] [Related]
50. Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication.
Flierl A; Oliveira LM; Falomir-Lockhart LJ; Mak SK; Hesley J; Soldner F; Arndt-Jovin DJ; Jaenisch R; Langston JW; Jovin TM; Schüle B
PLoS One; 2014; 9(11):e112413. PubMed ID: 25390032
[TBL] [Abstract][Full Text] [Related]
51. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
52. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
Schulz-Schaeffer WJ
Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
[TBL] [Abstract][Full Text] [Related]
53. Selectivity of Lewy body protein interactions along the aggregation pathway of α-synuclein.
Leitão ADG; Rudolffi-Soto P; Chappard A; Bhumkar A; Lau D; Hunter DJB; Gambin Y; Sierecki E
Commun Biol; 2021 Sep; 4(1):1124. PubMed ID: 34556785
[TBL] [Abstract][Full Text] [Related]
54. Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease.
Iwatsubo T
J Neurol; 2003 Oct; 250 Suppl 3():III11-4. PubMed ID: 14579119
[TBL] [Abstract][Full Text] [Related]
55. Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.
Junn E; Ronchetti RD; Quezado MM; Kim SY; Mouradian MM
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):2047-52. PubMed ID: 12576551
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology.
Gerard M; Deleersnijder A; Daniëls V; Schreurs S; Munck S; Reumers V; Pottel H; Engelborghs Y; Van den Haute C; Taymans JM; Debyser Z; Baekelandt V
J Neurosci; 2010 Feb; 30(7):2454-63. PubMed ID: 20164329
[TBL] [Abstract][Full Text] [Related]
57. Upregulation of α-synuclein following immune activation: Possible trigger of Parkinson's disease.
Kasen A; Houck C; Burmeister AR; Sha Q; Brundin L; Brundin P
Neurobiol Dis; 2022 May; 166():105654. PubMed ID: 35143968
[TBL] [Abstract][Full Text] [Related]
58. Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies.
Peng C; Gathagan RJ; Lee VM
Neurobiol Dis; 2018 Jan; 109(Pt B):209-218. PubMed ID: 28751258
[TBL] [Abstract][Full Text] [Related]
59. Anti-aggregation and fibril-destabilizing effects of sex hormones on alpha-synuclein fibrils in vitro.
Hirohata M; Ono K; Morinaga A; Ikeda T; Yamada M
Exp Neurol; 2009 Jun; 217(2):434-9. PubMed ID: 19289119
[TBL] [Abstract][Full Text] [Related]
60. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
